JP5572872B2 - 炎症性腸疾患を治療するための方法および組成物 - Google Patents

炎症性腸疾患を治療するための方法および組成物 Download PDF

Info

Publication number
JP5572872B2
JP5572872B2 JP2010545328A JP2010545328A JP5572872B2 JP 5572872 B2 JP5572872 B2 JP 5572872B2 JP 2010545328 A JP2010545328 A JP 2010545328A JP 2010545328 A JP2010545328 A JP 2010545328A JP 5572872 B2 JP5572872 B2 JP 5572872B2
Authority
JP
Japan
Prior art keywords
rifabutin
clarithromycin
clofazimine
auc
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010545328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511012A (ja
JP2011511012A5 (enExample
Inventor
ユリウス ボロディー，トーマス
ゴスラン，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of JP2011511012A publication Critical patent/JP2011511012A/ja
Publication of JP2011511012A5 publication Critical patent/JP2011511012A5/ja
Application granted granted Critical
Publication of JP5572872B2 publication Critical patent/JP5572872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010545328A 2008-02-08 2009-02-05 炎症性腸疾患を治療するための方法および組成物 Active JP5572872B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6514408P 2008-02-08 2008-02-08
US61/065,144 2008-02-08
PCT/AU2009/000129 WO2009097651A1 (en) 2008-02-08 2009-02-05 Methods and compositions for treating inflammatory bowel disease

Publications (3)

Publication Number Publication Date
JP2011511012A JP2011511012A (ja) 2011-04-07
JP2011511012A5 JP2011511012A5 (enExample) 2012-03-22
JP5572872B2 true JP5572872B2 (ja) 2014-08-20

Family

ID=40951740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545328A Active JP5572872B2 (ja) 2008-02-08 2009-02-05 炎症性腸疾患を治療するための方法および組成物

Country Status (18)

Country Link
US (10) US8343511B2 (enExample)
EP (2) EP2247291B1 (enExample)
JP (1) JP5572872B2 (enExample)
AU (1) AU2009212097B2 (enExample)
CA (1) CA2714043C (enExample)
CY (1) CY1121465T1 (enExample)
DK (1) DK2247291T3 (enExample)
ES (1) ES2708087T3 (enExample)
HR (1) HRP20190045T1 (enExample)
HU (1) HUE041305T2 (enExample)
IL (1) IL207420A (enExample)
NZ (1) NZ587250A (enExample)
PL (1) PL2247291T3 (enExample)
PT (1) PT2247291T (enExample)
SI (1) SI2247291T1 (enExample)
TR (1) TR201819940T4 (enExample)
WO (1) WO2009097651A1 (enExample)
ZA (1) ZA201005735B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587250A (en) 2008-02-08 2011-12-22 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
CA2883443C (en) 2012-08-30 2021-01-12 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell
WO2015123392A1 (en) * 2014-02-14 2015-08-20 The Texas A&M University System Compositions and methods for inhibition of angiogenesis and lymphangiogenesis
EP3145510B8 (en) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
EP3291798A4 (en) * 2015-05-04 2019-01-16 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF
BR112018003232A2 (pt) * 2015-10-06 2018-09-25 Redhill Biopharma Ltd terapias de combinação para tratamento de câncer
CN107202848B (zh) * 2017-07-24 2022-11-15 浙江华海药业股份有限公司 一种氯法齐明的液相色谱分析方法
EP3676580A4 (en) * 2017-08-29 2021-05-26 Weightrx Inc. SYSTEM AND PROCESS FOR AUTOMATED MONITORING OF CONSUMABLES
AU2020344214A1 (en) * 2019-09-12 2022-04-21 BioVersys AG Antibiotic combination therapies
CA3187031A1 (en) * 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2022204375A1 (en) * 2021-03-25 2022-09-29 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
DE69839261T2 (de) * 1997-04-01 2009-03-26 Borody, Thomas Julius, Five Dock Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
NZ587250A (en) 2008-02-08 2011-12-22 Red Hill Biopharma Ltd Methods and compositions for treating inflammatory bowel disease

Also Published As

Publication number Publication date
SI2247291T1 (sl) 2019-03-29
TR201819940T4 (tr) 2019-01-21
PL2247291T3 (pl) 2019-05-31
CA2714043A1 (en) 2009-08-13
US20140315841A1 (en) 2014-10-23
NZ587250A (en) 2011-12-22
US20110059136A1 (en) 2011-03-10
ES2708087T3 (es) 2019-04-08
CA2714043C (en) 2016-11-08
US10765691B2 (en) 2020-09-08
US20200030352A1 (en) 2020-01-30
HUE041305T2 (hu) 2019-05-28
IL207420A0 (en) 2010-12-30
US20170232028A1 (en) 2017-08-17
ZA201005735B (en) 2011-10-26
CY1121465T1 (el) 2020-05-29
US9314477B2 (en) 2016-04-19
EP3391882A1 (en) 2018-10-24
US11090326B2 (en) 2021-08-17
IL207420A (en) 2015-09-24
DK2247291T3 (en) 2019-01-21
US20130237488A1 (en) 2013-09-12
US20200206253A1 (en) 2020-07-02
EP2247291A4 (en) 2011-04-13
AU2009212097B2 (en) 2013-06-13
US9072763B2 (en) 2015-07-07
US20190060343A1 (en) 2019-02-28
HRP20190045T1 (hr) 2019-03-08
US10434114B2 (en) 2019-10-08
WO2009097651A1 (en) 2009-08-13
US9198926B2 (en) 2015-12-01
US10143702B2 (en) 2018-12-04
EP2247291A1 (en) 2010-11-10
JP2011511012A (ja) 2011-04-07
US10105379B2 (en) 2018-10-23
AU2009212097A1 (en) 2009-08-13
US20140243279A1 (en) 2014-08-28
PT2247291T (pt) 2019-02-01
EP2247291B1 (en) 2018-12-05
US20160228464A1 (en) 2016-08-11
US20180125872A1 (en) 2018-05-10
US8343511B2 (en) 2013-01-01

Similar Documents

Publication Publication Date Title
JP5572872B2 (ja) 炎症性腸疾患を治療するための方法および組成物
Bullingham et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients
Kirch et al. Dose‐dependence of the nifedipine‐digoxin interaction?
Lin et al. Effects of antacids and food on absorption of famotidine.
JP2020517660A (ja) ２−アミノ−ｌ−（２−（４−フルオロフェニル）−３−（４−フルオロフェニルアミノ）−８，８−ジメチル−５，６−ジヒドロイミダゾ［１，２−ａ］ピラジン−７（８ｈ）−イル）エタノン及びそれらの組み合わせの治療レジメン
WO2019074536A1 (en) METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY
Nishimagi et al. Progressive interstitial renal fibrosis due to Chinese herbs in a patient with calcinosis Raynaud esophageal sclerodactyly telangiectasia (CREST) syndrome
HK1262346A1 (en) Compositions comprising rifabutin, clarithromycin, and clofazimine
JP2024509823A (ja) アムセネストラントおよびパルボシクリブによる乳がんの処置
EP4065119A1 (en) Methods of treating pulmonary arterial hypertension
Moore et al. The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2025119266A1 (zh) 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
Arrillaga-Romany et al. ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140612

R150 Certificate of patent or registration of utility model

Ref document number: 5572872

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250